Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Adviespanel FDA positief over donanemab
jun 2024 | Dementie
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen
aug 2021 | Hoofdpijn